Last reviewed · How we verify
Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects.
This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects. Used for Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product.
At a glance
| Generic name | Azithromycin / Ivermectin / Ribaroxaban / Paracetamol |
|---|---|
| Also known as | with Ivermectin |
| Sponsor | Gilberto Cruz Arteaga |
| Drug class | Fixed-dose combination (antibiotic / antiparasitic / anticoagulant / analgesic) |
| Target | Multiple: bacterial 50S ribosome (azithromycin), glutamate-gated chloride channels (ivermectin), Factor Xa (rivaroxaban), COX enzymes (paracetamol) |
| Modality | Small molecule |
| Therapeutic area | Multi-indication (Infectious Disease / Parasitology / Cardiovascular / Pain Management) |
| Phase | Phase 3 |
Mechanism of action
Azithromycin is a macrolide antibiotic that binds to bacterial 50S ribosomal subunits. Ivermectin is an antiparasitic that enhances GABA-mediated chloride channel opening in parasites. Rivaroxaban is a direct factor Xa inhibitor that prevents thrombin generation. Paracetamol inhibits prostaglandin synthesis in the CNS. This unusual combination suggests either a compounded formulation or a non-standard investigational product.
Approved indications
- Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product
Common side effects
- Gastrointestinal disturbance (azithromycin)
- Pruritus and rash (ivermectin)
- Bleeding (rivaroxaban)
- Hepatotoxicity (paracetamol)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: